DARE earnings analysis
What we found in DARE's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Daré's Q2 revenue recovered to $187,546 from $(21,172) a year earlier, and the net loss narrowed 26% to $2,982,773, largely because grant offsets reduced reported R&D expense. However, the company remains heavily cash-consuming, with $12.3 million of operating cash outflow in the first six months, a $0.2 million working capital deficit, and substantial doubt regarding going-concern status. Near-term commercial launches and progress in Ovaprene and DARE-HPV provide catalysts, but Nasdaq delisting, additional financing needs, and FDA concerns regarding the Ovaprene trial are material overhangs.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue rebounded year over year
- Q2 2026 revenue was $187,546, up $208,718, or 986%, from $(21,172) in Q2 2025 and up from $152,455 in Q1 2026. The increase primarily reflected research and development services revenue under Gates Foundation agreements.
- Quarterly loss narrowed
- Q2 net loss improved 26% to $2,982,773 from $4,016,483 in Q2 2025, while operating expenses declined 26% to $2,835,637. The improvement was driven primarily by an $1,186,796, or 83%, reduction in R&D expense to $241,966.
- Non-dilutive funding offsets R&D
- Grant funding and other awards produced $4,017,949 of contra-R&D expense in Q2 2026, compared with $3,780,794 in Q2 2025. Six-month contra-R&D expense totaled $8,217,792, helping offset development spending.
- Initial commercial launches underway
- The company launched Flora Sync LF5 in June 2026 and expects to begin recording product revenue in July 2026. It also expects DARE to PLAY Sildenafil Cream to begin shipping and generating revenue in Q3 2026.
- Ovaprene study advances
- The Ovaprene DSMB reviewed 339 subjects and 1,789 menstrual cycles, with approximately 9% of women experiencing pregnancy and approximately 12% discontinuing due to vaginal odor, a 5% decrease from the July 2025 review. The FDA approved a protocol amendment, and management expects at least 2,500 cycles of exposure in 2027.
- DARE-HPV grant funding received
- The company received $1.5 million under its ARPA-H-supported DARE-HPV grant in May 2026, bringing cumulative receipts under the award to approximately $9.0 million of up to $10.0 million.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Going-concern and funding risk
- Management reported $12.6 million of cash and cash equivalents, a $0.2 million working capital deficit, a $6.0 million six-month net loss, and $12.3 million of six-month operating cash outflow. The filing states there is substantial doubt about the company's ability to continue as a going concern within 12 months.
- Nasdaq delisting risk
- Nasdaq determined on July 13, 2026 that stockholders' equity was below the $2.5 million requirement and that the company did not meet alternative thresholds of $35 million in market value of listed securities or $500,000 of net income. A hearing is scheduled for late August 2026, and any extension cannot exceed 180 days from the determination letter.
- Ovaprene regulatory uncertainty
- The FDA cautioned that removing the expectation of at least 250 Ovaprene completers could produce insufficient evidence for a favorable PMA decision and also questioned whether the study's Pearl Index performance goal is adequate. The study has so far included 339 subjects and 1,789 cycles against a protocol target of at least 2,500 cycles.
- Cash burn remains elevated
- Six-month operating cash outflow increased to $12,295,690 from $10,887,999 in the prior-year period. Cash used in investing activities was $80,586, primarily for property and equipment, while a $4.7 million decrease in deferred grant funding liability was a major working-capital use.
- Early commercialization execution risk
- Commercial revenue remains uncertain because DARE to PLAY relies on a third-party 503B outsourcing facility for manufacturing and required state-level licenses, while the company acknowledges it has no commercialization experience and limited infrastructure. Management does not expect DARE to PLAY revenue, if any, to be material during 2026.
- Government grant exposure
- Federal policy and funding uncertainty could affect development programs: the company states it has benefited significantly from federal grants and that approximately $9.0 million of up to $10.0 million has been received under the DARE-HPV award, while the status of other federal funding remains uncertain.
What they reported.
What the company itself reported, taken out of the document.
- Gross margin
- -70.6%
- Operating margin
- -1582.5%
What they said about what is next.
No numeric revenue or EPS guidance was provided. Management expects DARE to PLAY revenue to begin in Q3 2026, but does not expect such revenue, if any, to be material during 2026; cash and cash equivalents are expected to fund operations into Q4 2026. Management expects at least 2,500 Ovaprene menstrual cycles of exposure in 2027 and topline data from the Ovaprene and DARE-HPV studies in 2027.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 14, 2026
- Daré Bioscience, Inc. reported significant improvements in Q1 2026, with revenues increasing to $152,455 from $25,427 YoY, an impressive 500% growth driven by new service agreements. The company also disclosed a reduced…
- 10-K · March 26, 2026
- Daré expanded to a dual-path commercial strategy in 2025 and initiated commercialization of DARE to PLAY™ sildenafil cream in December 2025 while preparing a consumer vaginal probiotic (Flora Sync LF5™) for U.S. launch…
- 10-Q · November 13, 2025
- Daré reported Q3 2025 royalty revenue of $2,262 and a GAAP loss per share of $(0.28). Revenue collapsed versus Q3 2024 ($41,691) while operating loss narrowed to $(3,672,148) from $(4,681,349) a year earlier. Cash…
- 10-Q · May 13, 2025
- Daré reported Q1 2025 revenue of $25,427 (royalty revenue) versus $9,302 in Q1 2024, and a smaller net loss of $4.38 million (loss per share $0.50) versus a $6.76 million loss (loss per share $0.81) in the year-ago…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing DARE makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever